Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Depreciation & Amortization (CF) (2016 - 2025)

Protalix BioTherapeutics has reported Depreciation & Amortization (CF) over the past 16 years, most recently at $387000.0 for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $387000.0 for Q4 2025, up 15.87% from a year ago — trailing twelve months through Dec 2025 was $1.5 million (up 12.35% YoY), and the annual figure for FY2025 was $1.5 million, up 12.35%.
  • Depreciation & Amortization (CF) for Q4 2025 was $387000.0 at Protalix BioTherapeutics, up from $372000.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for PLX hit a ceiling of $387000.0 in Q4 2025 and a floor of $241000.0 in Q4 2021.
  • Median Depreciation & Amortization (CF) over the past 5 years was $299000.0 (2023), compared with a mean of $308000.0.
  • Biggest five-year swings in Depreciation & Amortization (CF): decreased 23.94% in 2021 and later grew 19.92% in 2022.
  • Protalix BioTherapeutics' Depreciation & Amortization (CF) stood at $241000.0 in 2021, then rose by 19.92% to $289000.0 in 2022, then rose by 8.3% to $313000.0 in 2023, then increased by 6.71% to $334000.0 in 2024, then rose by 15.87% to $387000.0 in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $387000.0 (Q4 2025), $372000.0 (Q3 2025), and $360000.0 (Q2 2025) per Business Quant data.